What impact does a global pandemic like the COVID-19 emergency have on the work of a multinational pharmaceutical company? Luca Crippa, CEO & Managing Director of IBSA Farmaceutici, answered this and other questions during the international webinar run by IMCAS ACADEMY in October; a global reference point for dermatology, plastic surgery and aesthetic medicine.
“For the entire duration of the first lockdown,” Crippa explained, “we felt it was our duty to guarantee therapeutic continuity to patients. We worked at all levels to the best of our ability, rapidly accelerating innovation in internal company processes. At IBSA, we have the advantage of controlling the entire company value chain, from production to distribution, which allowed us to act at all levels to overcome critical issues. In short, throughout this pandemic, IBSA has demonstrated a very high level of resilience and we’re all very proud of the result.”
Safety, both internal and external to the company, has been another central point of all our strategies since March: “We’ve put every possible initiative in place at all the company's sites, applying all the regulations in force and adding, where possible, even stricter protocols.”
The other innovation introduced during lockdown has been to use modern remote learning tools to maintain proximity to scientific partners, which are fundamental both for the development of new products, which has never stopped, and for daily activities, both in the production and R&D sectors.